40 results on '"Fung, Leah"'
Search Results
2. Data from Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth
3. Supplementary Figure S3 from Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth
4. Supplementary Table S3 from Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth
5. Supplementary Methods from Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth
6. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth
7. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance
8. Abstract B002: Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers
9. First-in-class PDE4D bifunctional degraders for inflammatory skin diseases
10. Abstract 1578: Novel Cereblon mediated bifunctional degraders of SOS1 for treatment of pan-KRAS mutant tumors
11. Abstract 17055: Novel Dual mTOR Inhibitor/AMPK Activator Mitigates Doxorubicin Cardiotoxicity and Potentiates Its Chemotherapeutic Efficacy Against Triple Negative Breast Cancer
12. BTX-1188, a first-in-class dual degrader of GSPT1 and IKZF1/3, for treatment of acute myeloid leukemia (AML) and solid tumors.
13. Bioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
14. Abstract 1963: Targeting hematological malignancies with two functionally and mechanistically distinct classes of cereblon mediated protein homeostatic modulators
15. Abstract LB-211: Synergistic anti-metastatic effect of pembrolizumab in combination with a novel mTORC1 inhibitor/AMPK agonist in a CAM metastatic triple negative breast cancer model
16. Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies
17. Targeting AML: The Development of Two Functionally and Mechanistically Distinct Classes of Cereblon-Mediated Protein Homeostatic Modulators
18. SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF
19. A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure
20. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models
21. Abstract 14309: A Novel Fibroblast Activation Inhibitor, NM922, Attenuates Maladaptive Fibrotic Remodeling to Preserve Cardiac Function Following the Onset of Heart Failure
22. Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers.
23. Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer.
24. Abstract 4527: Oral multi-pathway inhibitors for the treatment of triple negative breast cancer
25. Abstract B109: Novel orally bioavailable triple-negative breast cancer drug candidates that prevent the development of cancer associated fibroblasts in the tumor stroma
26. Abstract 3830: Novel small molecule translation inhibitors with safety and efficacy in triple negative breast cancer (TNBC) animal models
27. Two New Classes of Drugs to Target Chemotherapy Resistant and High Risk B-ALL
28. Structure—Activity Relationship Studies of Ethyl 2‐[(3‐Methyl‐2,5‐dioxo(3‐pyrrolinyl))amino] ‐4‐(trifluoromethyl)pyrimidine‐5‐carboxylate: An Inhibitor of AP‐1 and NF‐ϰB Mediated Gene Expression.
29. Structure–Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF-κB Mediated Gene Expression
30. Differential Response of Estrogen Receptors α and β to SP500263, a Novel Potent Selective Estrogen Receptor Modulator
31. Inhibitors of NF-κB and AP-1 Gene Expression: SAR Studies on the Pyrimidine Portion of 2-Chloro-4-trifluoromethylpyrimidine-5-[N-(3‘,5‘-bis(trifluoromethyl)phenyl)carboxamide]
32. Solution-phase parallel synthesis using ion-exchange resins
33. Differential response of estrogen receptors alpha and beta to SP500263, a novel potent selective estrogen receptor modulator.
34. Abstract 15913: Novel Dual MTOR Inhibitors/AMPK Activators Attenuate Doxorubicin-Induced Cardiotoxicity
35. Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma
36. A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure.
37. SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF.
38. Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF-kappaB mediated gene expression.
39. Differential response of estrogen receptors alpha and beta to SP500263, a novel potent selective estrogen receptor modulator.
40. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.